{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T05:23:19Z","timestamp":1746422599166,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":28,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071621677"},{"type":"electronic","value":"9781071621684"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-2168-4_10","type":"book-chapter","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T17:05:21Z","timestamp":1643907921000},"page":"177-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recombinant Modified Vaccinia Virus Ankara Development to Express VP2, NS1, and VP7 Proteins of Bluetongue Virus"],"prefix":"10.1007","author":[{"given":"Alejandro","family":"Mar\u00edn-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Utrilla-Trigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Jim\u00e9nez-Cabello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Ortego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2174\/1568005033481123","volume":"3","author":"G Sutter","year":"2003","unstructured":"Sutter G, Staib C (2003) Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3:263\u2013271. https:\/\/doi.org\/10.2174\/1568005033481123","journal-title":"Curr Drug Targets Infect Disord"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1006\/viro.1998.9123","volume":"244","author":"G Antoine","year":"1998","unstructured":"Antoine G, Scheiflinger F, Dorner F et al (1998) The complete genomic sequence of the modified vaccinia ankara strain: comparison with other orthopoxviruses. Virology 244:365\u2013396. https:\/\/doi.org\/10.1006\/viro.1998.9123","journal-title":"Virology"},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4161\/hv.9693","volume":"5","author":"M Esteban","year":"2009","unstructured":"Esteban M (2009) Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV\/AIDS. Hum Vaccin 5:867\u2013871. https:\/\/doi.org\/10.4161\/hv.9693","journal-title":"Hum Vaccin"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.virusres.2013.11.013","volume":"182","author":"E Calvo-Pinilla","year":"2014","unstructured":"Calvo-Pinilla E, Castillo-Olivares J, Jabbar T et al (2014) Recombinant vaccines against bluetongue virus. Virus Res 182:78\u201386. https:\/\/doi.org\/10.1016\/j.virusres.2013.11.013","journal-title":"Virus Res"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.4161\/hv.28974","volume":"10","author":"J Garc\u00eda-Arriaza","year":"2014","unstructured":"Garc\u00eda-Arriaza J, Esteban M (2014) Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother 10:2235\u20132244. https:\/\/doi.org\/10.4161\/hv.28974","journal-title":"Hum Vaccin Immunother"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1128\/JVI.74.2.923-933.2000","volume":"74","author":"JC Ram\u00edrez","year":"2000","unstructured":"Ram\u00edrez JC, Gherardi MM, Esteban M (2000) Biology of attenuated modified vaccinia virus ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western reserve strain and advantages as a vaccine. J Virol 74:923\u2013933","journal-title":"J Virol"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","volume":"97","author":"A Volz","year":"2017","unstructured":"Volz A, Sutter G (2017) Modified vaccinia virus ankara. Adv Virus Res 97:187\u2013243. https:\/\/doi.org\/10.1016\/bs.aivir.2016.07.001","journal-title":"Adv Virus Res"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.4049\/jimmunol.176.8.4682","volume":"176","author":"A Le Bon","year":"2006","unstructured":"Le Bon A, Durand V, Kamphuis E et al (2006) Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 176:4682\u20134689. https:\/\/doi.org\/10.4049\/jimmunol.176.8.4682","journal-title":"J Immunol"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/1042819031000149368","volume":"45","author":"DF Tough","year":"2004","unstructured":"Tough DF (2004) Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 45:257\u2013264. https:\/\/doi.org\/10.1080\/1042819031000149368","journal-title":"Leuk Lymphoma"},{"key":"10_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07772-z","volume":"9","author":"B Hern\u00e1ez","year":"2018","unstructured":"Hern\u00e1ez B, Alonso-Lobo JM, Montanuy I et al (2018) A virus-encoded type I interferon decoy receptor enables evasion of host immunity through cell-surface binding. Nat Commun 9:e7772. https:\/\/doi.org\/10.1038\/s41467-018-07772-z","journal-title":"Nat Commun"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1089\/jir.2009.0073","volume":"29","author":"B Perdiguero","year":"2009","unstructured":"Perdiguero B, Esteban M (2009) The interferon system and vaccinia virus evasion mechanisms. J Interf Cytokine Res 29:581\u2013598. https:\/\/doi.org\/10.1089\/jir.2009.0073","journal-title":"J Interf Cytokine Res"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1099\/vir.0.055921-0","volume":"94","author":"GL Smith","year":"2013","unstructured":"Smith GL, Benfield CTO, Maluquer de Motes C et al (2013) Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J Gen Virol 94:2367\u20132392. https:\/\/doi.org\/10.1099\/vir.0.055921-0","journal-title":"J Gen Virol"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.vaccine.2019.10.087","volume":"38","author":"A Mar\u00edn-L\u00f3pez","year":"2020","unstructured":"Mar\u00edn-L\u00f3pez A, Barreiro-Pi\u00f1eiro N, Utrilla-Trigo S et al (2020) Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara. Vaccine 38:882\u2013889. https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.087","journal-title":"Vaccine"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.antiviral.2018.04.015","volume":"154","author":"E Calvo-Pinilla","year":"2018","unstructured":"Calvo-Pinilla E, Gubbins S, Mertens P et al (2018) The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host. Antivir Res 154:132\u2013139. https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.015","journal-title":"Antivir Res"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1016\/j.vaccine.2014.04.036","volume":"32","author":"B Alberca","year":"2014","unstructured":"Alberca B, Bachanek-Bankowska K, Cabana M et al (2014) Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge. Vaccine 32:3670\u20133674. https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.036","journal-title":"Vaccine"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.virusres.2015.08.005","volume":"210","author":"F de la Poza","year":"2015","unstructured":"de la Poza F, Mar\u00edn-L\u00f3pez A, Castillo-Olivares J et al (2015) Identification of CD8 T cell epitopes in VP2 and NS1 proteins of African horse sickness virus in IFNAR(\u2212\/\u2212) mice. Virus Res 210:149\u2013153. https:\/\/doi.org\/10.1016\/j.virusres.2015.08.005","journal-title":"Virus Res"},{"key":"10_CR17","first-page":"3403","volume":"5","author":"S Chakrabarti","year":"1985","unstructured":"Chakrabarti S, Brechling K, Moss B (1985) Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 5:3403\u20133409","journal-title":"Mol Cell Biol"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/vaccines8030346","volume":"8","author":"S Utrilla-Trigo","year":"2020","unstructured":"Utrilla-Trigo S, Jim\u00e9nez-Cabello L, Alonso-Ravelo R et al (2020) Heterologous combination of ChAdOx1 and MVA vectors expressing protein NS1 as vaccination strategy to induce durable and cross-protective CD8+ T cell immunity to bluetongue virus. Vaccine 8:346. https:\/\/doi.org\/10.3390\/vaccines8030346","journal-title":"Vaccine"},{"key":"10_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00938-18","volume":"92","author":"A Mar\u00edn-L\u00f3pez","year":"2018","unstructured":"Mar\u00edn-L\u00f3pez A, Calvo-Pinilla E, Barriales D et al (2018) CD8 T cell responses to an immunodominant epitope within the nonstructural protein NS1 provide wide immunoprotection against bluetongue virus in IFNAR \u2212\/\u2212 mice. J Virol 92:e00938-18. https:\/\/doi.org\/10.1128\/JVI.00938-18","journal-title":"J Virol"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.virusres.2013.12.002","volume":"180","author":"E Calvo-Pinilla","year":"2014","unstructured":"Calvo-Pinilla E, de la Poza F, Gubbins S et al (2014) Vaccination of mice with a modified vaccinia ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation. Virus Res 180:23\u201330. https:\/\/doi.org\/10.1016\/j.virusres.2013.12.002","journal-title":"Virus Res"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.virusres.2013.09.038","volume":"182","author":"J Ortego","year":"2014","unstructured":"Ortego J, de la Poza F, Mar\u00edn-L\u00f3pez A (2014) Interferon \u03b1\/\u03b2 receptor knockout mice as a model to study bluetongue virus infection. Virus Res 182:35\u201342. https:\/\/doi.org\/10.1016\/j.virusres.2013.09.038","journal-title":"Virus Res"},{"key":"10_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070197","volume":"8","author":"F de la Poza","year":"2013","unstructured":"de la Poza F, Calvo-Pinilla E, L\u00f3pez-Gil E et al (2013) Ns1 is a key protein in the vaccine composition to protect Ifnar(\u2212\/\u2212) mice against infection with multiple serotypes of African horse sickness virus. PLoS One 8:e70197. https:\/\/doi.org\/10.1371\/journal.pone.0070197","journal-title":"PLoS One"},{"key":"10_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060574","volume":"8","author":"TK Jabbar","year":"2013","unstructured":"Jabbar TK, Calvo-Pinilla E, Mateos F et al (2013) Protection of IFNAR (\u2212\/\u2212) mice against bluetongue virus serotype 8, by heterologous (DNA\/rMVA) and homologous (rMVA\/rMVA) vaccination, expressing outer-capsid protein VP2. PLoS One 8:e60574. https:\/\/doi.org\/10.1371\/journal.pone.0060574","journal-title":"PLoS One"},{"key":"10_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034735","volume":"7","author":"E Calvo-Pinilla","year":"2012","unstructured":"Calvo-Pinilla E, Navasa N, Anguita J et al (2012) Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus. PLoS One 7:e34735. https:\/\/doi.org\/10.1371\/journal.pone.0034735","journal-title":"PLoS One"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.vaccine.2009.10.027","volume":"28","author":"E Calvo-Pinilla","year":"2009","unstructured":"Calvo-Pinilla E, Rodr\u00edguez-Calvo T, Sevilla N et al (2009) Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(\u2212\/\u2212) mice against lethal bluetongue infection. Vaccine 28:437\u2013445. https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.027","journal-title":"Vaccine"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/microorganisms9010042","volume":"9","author":"L Jim\u00e9nez-Cabello","year":"2021","unstructured":"Jim\u00e9nez-Cabello L, Utrilla-Trigo S, Calvo-Pinilla E et al (2021) Viral vector vaccines against bluetongue virus. Microorganisms 9:42. https:\/\/doi.org\/10.3390\/microorganisms9010042","journal-title":"Microorganisms"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-020-00218-y","volume":"5","author":"E Calvo-Pinilla","year":"2020","unstructured":"Calvo-Pinilla E, Mar\u00edn-L\u00f3pez A, Moreno S et al (2020) A protective bivalent vaccine against Rift valley fever and bluetongue. Vaccine 5:1\u201312. https:\/\/doi.org\/10.1038\/s41541-020-00218-y","journal-title":"Vaccine"},{"key":"10_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.antiviral.2017.03.010","volume":"142","author":"A Mar\u00edn-L\u00f3pez","year":"2017","unstructured":"Mar\u00edn-L\u00f3pez A, Calvo-Pinilla E, Barriales D et al (2017) Microspheres-prime\/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(\u2212\/\u2212) mice conferring protection against serotypes 1 and 4 of bluetongue virus. Antivir Res 142:55\u201362. https:\/\/doi.org\/10.1016\/j.antiviral.2017.03.010","journal-title":"Antivir Res"}],"container-title":["Methods in Molecular Biology","Vaccine Technologies for Veterinary Viral Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2168-4_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T02:01:06Z","timestamp":1662170466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2168-4_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9781071621677","9781071621684"],"references-count":28,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2168-4_10","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"3 February 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}